50 results about "Musculoskeletal disorder" patented technology

Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery / transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.

A non-invasive device for assisting the treatment of any kind of musculoskeletal disorder, including but not exclusive of those of joint, limb, and spine disorders, includes a brace, sleeve, flexible pad, or any combination of the three, a plurality of electrodes disposed thereon, wherein the plurality of electrodes transmit at least three electrophysical modalities, and a stimulation control unit having interactive software to establish a controlled sequence of transmission of the at least three electrophysical modalities and communicating the controlled sequence to the electrodes. The at least three electrophysical modalities are chosen from a group consisting of neuromodulating functional electrical stimulation, transcutaneous electrical nerve stimulation, pulsed electromagnetic field stimulation, and heat therapy stimulation. The stimulation control unit also provides feedback data using the electrodes for monitoring and integration with the interactive software to analyze and assess biomechanical, neuromuscular, and neurological responses to the device.

Medical devices with novel spark gap electrode designs, able to control manually or automatically the electrodes gap are provided. These devices are used to generate a shock wave created by the rapid expansion and collapse of a plasma bubble that is formed between two spark gap electrodes placed in a special liquid medium, when a high differential voltage (kV) is applied to the electrodes. The resulting shock wave impacts a reflector to direct the energy into the body of an animal or a human toward the desired treatment location. This electro-hydraulic principle to create acoustic shock waves as a method of treatment is in use in the medical (lithotripsy, orthopedic use, wound treatment, burns, post-operative treatment, pain treatment, diagnosis, skin and organ transplantation supporting devices, arteriosclerosis treatment), cosmetic (treatment of scars and cellulite) and veterinary (treatment of musculoskeletal disorders) fields.

A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.

The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and / or heart failure, and augmentation of this function can be used to repress slow fiber genes and activate fast fiber genes in the treatment of musculoskeletal disorders.

The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., Pd(II)-, Ni(II)-, or Fe(II)-ligand of Formula (A)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers Y. The provided supramolecular complexes are able to form gels (e.g., hydrogels). The gels are suprametallogels and exhibited excellent mechanical properties without sacrificing self-healing and showed high robustness and storage modulus. The present disclosure further provides compositions (e.g., gels) that include the nanostructures or supramolecular complexes and optionally an agent (e.g., small molecule), where the nanostructures and the nanostructure moieties of the supramolecular complexes may encapsulate and slowly release the agent. The nanostructures, supramolecular complex, and compositions may be useful in delivering an agent to a subject, tissue, or cell, as super-absorbent materials, and in treating a disease (e.g., a genetic diseases, proliferative disease (e.g., cancer or benign neoplasm), hematological disease, neurological disease, gastrointestinal disease (e.g., liver disease), spleen disease, respiratory disease (e.g., lung disease), painful condition, genitourinary disease, musculoskeletal condition, infectious disease, inflammatory disease, autoimmune disease, psychiatric disorder, or metabolic disorder).

The present invention relates to the identification of two microRNAs, miR-499 and miR-208b, that repress fast skeletal muscle contractile protein genes. Expression of miR-499 and / or miR-208b can be used to repress fast fiber genes and activate slow fiber genes in the treatment of musculoskeletal disorders. Inhibition of miR-499 and / or miR-208b is proposed as a treatment for cardiac hypertrophy, myocardial infarction, and / or heart failure. Pharmaceutical compositions comprising antagonists and agonists of miR-499 and miR-208b function are also disclosed.

The present invention relates to methods, compositions, and kits for detecting and quantitating exosomes and exosomal biomarkers and the use of exosomes and exosomal biomarkers in diagnostic and prognostic methods for various diseases and disorders. Disease and disorders of the present invention include neurological disorders, immunological disorders, placental diseases, cancer, hematological disorders, kidney disease, gastrointestinal diseases, liver diseases, and musculoskeletal diseases

Disclosed are devices, systems and methods that utilize bioprinters to form scaffold structures in situ to facilitate treatment of the musculoskeletal or skin disorders in patients. A method for treating a musculoskeletal disorder of a patient includes positioning a bioprinter at a situs of the musculoskeletal disorder, or a situs of a skin injury, in the patient. The method includes extruding a hydrogel formulation from the bioprinter into the situs. The method includes curing the hydrogel formulation in the situs. The hydrogel formulation has a composition effective to generate, upon the curing, a scaffold structure in the situs to facilitate muscle hypertrophy, or skin wound healing, in the situs.

A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration-time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.

The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject including determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of the autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject-either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit.

The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.

The present invention provides a method of treating or preventing cardiac disorders in a subject in need thereof by inhibiting the expression or function of both miR-499 and miR-208 in the heart cells of the subject. In particular, specific protocols for administering inhibitors of the two miRNAs that achieve efficient, long-term suppression are disclosed. In addition, the invention provides a method for treating or preventing musculoskeletal disorders in a subject in need thereof by increasing the expression or activity of both miR-208 and miR-499 in skeletal muscle cells of the subject.

Provided is a formulation containing amorphous or microcrystalline calcium carbonate finely interspersed with organic matter in a ratio of 10 parts of the carbonate per 1 to 3 parts of the organic matter, wherein the organic matter consists of chitin and polypeptide. The formulation is efficient in treating various pathological conditions, including proliferative diseases, neurological disorders, and musculoskeletal disorders.

Disclosed herein are novel assays, systems and kits for generating a personalized or stratified diagnostic report, e.g., to facilitate selection of an appropriate treatment of a musculoskeletal disease or disorder in a subject. The assays and systems are based on detecting and / or measuring in vitro anabolic responses of musculoskeletal cells or precursor cells thereof to a panel of test compositions (e.g., test compositions each comprising at least one agent selected to maintain and / or increase muscle and / or bone growth), and ranking the ability of each test composition to stimulate muscle and bone growth. The resultant ranks of the test compositions can then be used to identify, select, and / or optimize a treatment regimen for the subject who is determined to have, or have a risk, a musculoskeletal disease or disorder. Methods for treating and / or preventing a musculoskeletal disease or disorder are also provided herein.

The present invention relates to gene therapy delivery and expression systems comprising at least one helper-dependent adenoviral vector containing a nucleic acid sequence encoding for proteoglycan 4 (PRG4) or a biologically active fragment thereof. The invention further relates to a pharmaceutical composition comprising a therapeutically effective amount of at least one helper-dependent adenoviral vector containing said nucleic acid sequence encoding for proteoglycan 4 (PRG4), or a homolog thereof from any other species, or a biologically active fragment thereof. The invention also relates to the use of the novel gene therapy delivery and expression system according to the invention for use in the prevention and / or treatment of camptodactyly-arthropathy-coxa vara-pericarditis (CACP), or a musculoskeletal disorder such as a joint disorder or joint disease.

A method for the treatment and prophylaxis of diseases or conditions associated with aging which includes oxidative stress and cancer. Such diseases or conditions are associated with a decrease or increase presence of one or a combination of one or more Carbonic Anhydrase isozymes I TO VII in the tissue of a subject. These diseases include but are not limited to chronic neurodegenerative diseases such as Alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, immune disorders which includes systemic lupus erythematosus, diabetes mellitus; musculo-skeletal disorders which includes osteoporosis,arthritis, osteomalacia. Cancer which includes the breast, lung, colon, prostate gland, ovary, esophagus, liver, rectum. The method comprises administering to the patient a pharmaceutically effective non toxic amount of one or a combination of one or more compounds that increases or decreases the level of one or more Cell Specific Carbonic Anhydrase Enzymes whose levels have been increased or decreased in the tissue of the subject. Such compound maybe the Cell Specific Carbonic Anhydrase Enzymes I to VII. A compound that when absorbed reacts or dissociates to form cell specific carbonic enzymes or one or more compounds that when administered promotes the increase or decrease level of one or more cell specific Carbonic anhydrase I,II,III,IV,V,VI,VII. As growth factors of stem cells as an alternative to stem cell therapy. These methods includes the administering of one or a combination of one or more of these compounds over an extended period of time ranging from 6 months until the patient dies.

The disclosure is directed to a system and methods for dynamic diagnosis of musculoskeletal conditions. The methods include monitoring at least one body part of a subject with at least one sensor, the at least one sensor configured to detect motions of the at least one body part of the subject, the at least one sensor comprising a Micro Electro Mechanical System (MEMS) sensor. The at least one sensor transmits kinematic data to a signature-comparing device. The methods include obtaining composite signatures of the subject based on the kinematic data, the composite signatures comprising at least one motion signature. The methods also include comparing the composite signatures of the subject to a normal composite signature to determine whether a difference between the composite signatures of the subject and the normal composite signatures is larger than a pre-determined threshold.

The present invention relates to a composition comprising an oligomeric compound comprising one or more tricyclo-deoxyribonucleic acid (tc-DNA) nucleosides and one or more lipid moiety, wherein said one or more lipid moiety is covalently linked to said oligomeric compound either directly or via a spacer, and wherein preferably said oligomeric compound comprises from 5 to 40 monomer subunits, as well as pharmaceutical compositions thereof and their uses in the prevention or treatment of neuromuscular or musculoskeletal diseases such as Duchenne muscular dystrophy or Steinert disease.

An apparatus for determining a musculoskeletal disease may be disclosed. The apparatus may include a motion protocol learning unit configured to generate a first motion protocol used to determine a musculoskeletal disease in advance through learning, a motion protocol recognition model unit configured to generate a motion protocol recognition model for determining a musculoskeletal disease by using information of the first motion protocol, a body pose estimator configured to receive a user image to be recognized and estimate a body pose from the user image, and a disease classification and prediction unit configured to determine a musculoskeletal disease by matching the body pose and the motion protocol recognition model.

Systems and methods for treating musculo skeletal disorders of the spinopelvic anatomy including treating spinal deformities by spinopelvic fixation including fusion of the sacroiliac joint at the base of long spinal fusion construct cases. The system may include implants designed to be used as an adjunct to long spinal fusions to further the immobilization and stabilization of the sacroiliac joint. The implants may be designed to augment an S2AI screw and an S1 screw in order to improve durability of the foundation of the spinal construct. The implants may have a triangular cross section.

The invention discloses an external traditional Chinese medicine composition for treating various muscle and bone diseases and a preparation device thereof. The traditional Chinese medicine composition provided by the invention is divided into a formula I and a formula II. The formula 1 is used for stopping bleeding, stopping pain, and relieving swelling, and can be used for treating early traumatic injury; and the formula 2 is used for dispelling pathogenic wind and cold, removing dampness, promoting blood circulation, removing blood stasis, dredging collaterals, and promoting bone regeneration. The formula I and the formula II are matched for use, and have good effects. Meanwhile, all the raw materials of the invention are reasonably matched and have synergistic effect, and the formulasare combined and matched, so that the composition has the effects of dispelling pathogenic wind and cold, removing dampness, stopping bleeding, stopping pain, promoting blood circulation, dispelling blood stasis, and dredging channels and collaterals, and is widely applicable to myofascitis, lumbar muscle strain, cervical and lumbar disc herniation and senile osteoporosis accompanied with compression fracture caused by traumatic injury, sprain and exogenous evil, blue soft tissues and blood stasis caused by fracture caused by trauma, and pain, swelling, and limb function limitation caused by bone injury.

The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and / or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.

The invention is directed to the use of a formulation comprising meloxicam or a pharmacologically acceptable meloxicam salt of an organic or inorganic base thereof for the long-term treatment of musculoskeletal disorders in cats. No negative effects on renal function occur following a treatment from 10 to 20 months or more.

An apparatus and method to convert a dental, oral, orthodontic appliances, retainers, and dentures into a multifunctional oral appliance. The apparatus includes plurality of mechanical connectors and attachments made of plastic, ceramic, or metal, that convert any dental or oral appliances, into multipurpose, three dimensionally adjustable oral appliances for treating obstructive sleep apnea, snoring, temporomandibular joint and musculoskeletal disorders of the jaw, and for improving breathing from the mouth even when nasal passages are blocked.

The invention relates to polymer particles combined with hyaluronic acid molecules or hyaluronate and a preparation method thereof, the polymer particles are composed of poly(lactic acid-co-glycolic acid) (PLGA) polymers, poly(lactic acid-co -glycolic acid)-polyethylene glycol-poly(lactic acid-co-glycolic acid) (PLGA-PEG-PLGA) copolymer, or mixtures thereof. The invention also relates to injectable cosmetic or pharmaceutical compositions containing such polymer particles, processes for the preparation of such compositions and their use as medicines (in particular for the prophylaxis and / or Treatment of: musculoskeletal disorders, traumatic conditions of the skin and skin diseases, oral symptoms, dryness of the vaginal mucous membranes and urinary tract infections or cystitis, dry eye membranes and eye infections, and obesity), and their role in preventing skin aging and / or repairing the dermis Use in tissue (mesotherapy). More specifically, the compositions of the present invention may be aimed at replenishing joint fluid, especially synovial fluid, reestablishing the rheological and physiological conditions of pathological joints (e.g. arthritic joints), or effectively remodeling, moisturizing and protecting the skin. Treats and repairs the epidermis.

The invention relates to the use of a cyclic glycopeptide to enhance the resistance of a composition to one or more of a tensile, shear and torsional force, where the composition comprises a bone substitute powder, an aqueous liquid and the cyclic glycopeptide. The invention also relates to a composition for use in the treatment of a musculoskeletal disorder in a mammal receiving an implant to enhance bone re-growth for stabilization of the implant, and to a method for the use of the composition in treatment of the mammal. The composition comprises a bone substitute powder, an aqueous liquid and a cyclic glycopeptide.